Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

MetricABVXAbivax SAGMABGenmab A/SINCYIncyte
Snapshot
Price$145.95$28.11$116.86
Market cap$11.63B$16.18B$23.35B
Valuation
P/E—20.9x16.3x
Forward P/E—27.9x11.7x
Growth
Revenue growth—20.7%21.5%
EPS growth—-25.3%2455.3%
Profitability
Net margin—21.1%26.7%
ROE-51.7%14.5%29.2%
Balance sheet & cash
Debt / equity0x0.93x0.01x
Free cash flow yield-2.1%—2.2%
Dividend yield———
Verdict
Investment ratingWeak· 35Favorable· 62Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearABVXtoday $146GMABtoday $28INCYtoday $117
2027$117.12 – $171.78+18% CAGR$21.50 – $31.54+12% CAGR$2,239.60 – $3,284.75+2711% CAGR
2028$125.32 – $183.81+12% CAGR$21.93 – $32.17+7% CAGR$57,228.76 – $83,935.51+2580% CAGR
2029$134.10 – $196.67+10% CAGR$22.37 – $32.81+5% CAGR$1,462,372.22 – $2,144,812.59+2538% CAGR
2030$143.48 – $210.44+10% CAGR$22.82 – $33.47+4% CAGR$37,368,143.63 – $54,806,610.65+2517% CAGR
2031$153.53 – $225.17+9% CAGR$23.28 – $34.14+4% CAGR$954,871,910.91 – $1,400,478,802.66+2504% CAGR
5-yr CAGR1.0% – 9.1%-3.7% – 4.0%2312.4% – 2504.5%